Compare Merck & Co., Inc. (MRK) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NIO Inc. — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while NIO Inc. trades at $3.65 (market cap $9.23B). The key difference: Merck & Co., Inc. is far larger — about 39.7× NIO Inc.'s market cap, and Merck & Co., Inc. pays a 2.29% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| MRK | NIO | |
|---|---|---|
Market Cap | $366.28B | $9.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $7.89 |
52-Week Low | $77.60 | $3.70 |
Enterprise Value | $413.04B | $7.13B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
NIO trades at $3.79, down 0.26% over 24 hours, with a bearish technical signal but improving fundamentals. Recent Q2 2026 earnings beat expectations with a narrower loss, while revenue grew 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03). The stock faces headwinds from a weak Chinese EV market but shows progress toward profitability with positive operating cash flow in Q2.
The outlook is mixed: analyst consensus is bullish with a $5.50 price target (50% buy ratings), but risks include high debt, competition, and macroeconomic pressures. Upside depends on sustained delivery growth and margin expansion, while downside risks loom from cost inflation and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
